4. Immunogenicity of the Adjuvanted Recombinant Zoster Vaccine in Immunocompromised Adults

BACKGROUND: Immunocompromised (IC) populations are at increased risk of developing herpes zoster (HZ) due to disease- and/or therapy-induced immunosuppression. The adjuvanted recombinant zoster vaccine (RZV) has demonstrated 68.2% efficacy in preventing HZ in autologous hematopoietic stem cell trans...

Descripción completa

Detalles Bibliográficos
Autores principales: Dagnew, Alemnew F, Vink, Peter, Drame, Mamadou, Willer, David, Salaun, Bruno, Schuind, Anne
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Oxford University Press 2020
Materias:
Oral Abstracts
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7776102/
http://dx.doi.org/10.1093/ofid/ofaa417.003

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7776102/
http://dx.doi.org/10.1093/ofid/ofaa417.003

Ejemplares similares